Abstract
Tardive dyskinesia is a severe debilitating movement disorder characterized by choreoathetotic movements developing in one-fifth of the patients with schizophrenia. In this study we have investigated the significance of CYP3A4*1B and CYP2D6*4 polymorphisms in TD susceptibility among chronic schizophrenia patients (n = 335) from north India. Tardive dyskinesia was diagnosed in approximately 29% (96/335) of these patients. No significant association of either of the two SNPs with TD (CYP3A4*1B chi2 = 0. 308, df = 1, p = 0.579; CYP2D6*4 chi2 = 0.006, df = 1, p = 0.935) was observed. However a trend towards increased severity of TD in patients heterozygous for the CYP2D6*4 mutation was observed.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Analysis of Variance
-
Antipsychotic Agents / adverse effects
-
Asian People / genetics
-
Case-Control Studies
-
Cross-Sectional Studies
-
Cytochrome P-450 CYP2D6 / genetics*
-
Cytochrome P-450 CYP3A
-
Cytochrome P-450 Enzyme System / genetics*
-
Dyskinesia, Drug-Induced / ethnology
-
Dyskinesia, Drug-Induced / genetics*
-
Genetic Predisposition to Disease / ethnology
-
Genetic Predisposition to Disease / genetics*
-
Humans
-
India / epidemiology
-
Pharmacogenetics
-
Polymorphism, Single Nucleotide
-
Retrospective Studies
-
Schizophrenia / drug therapy
Substances
-
Antipsychotic Agents
-
Cytochrome P-450 Enzyme System
-
CYP3A protein, human
-
Cytochrome P-450 CYP2D6
-
Cytochrome P-450 CYP3A
-
CYP3A4 protein, human